💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Adenovirus Type 26 Encoding Sars-Cov-2 Spike Glycoprotein

CHEMBL6068381 Phase 4 Approuvé Vaccine component
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This vaccine component uses a harmless, modified adenovirus to carry genetic instructions for the SARS-CoV-2 spike protein found on the coronavirus surface. Once administered, it prompts the immune system to produce antibodies and cellular defenses against COVID-19 without exposing the recipient to the live virus.

Mécanisme d'action

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This vaccine component uses a harmless, modified adenovirus to carry genetic instructions for the SARS-CoV-2 spike protein found on the coronavirus surface. Once administered, it prompts the immune system to produce antibodies and cellular defenses against COVID-19 without exposing the recipient to the live virus.

Stimulates the adaptive immune system to produce antigen-specific antibodies and memory cells, providing protective immunity against subsequent exposure to the pathogen.

Yes, Adenovirus Type 26 Encoding Sars-Cov-2 Spike Glycoprotein is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068381. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.